

May 7, 2019

Trans Chromosomics, Inc.

Trans Chromosomics concludes a tripartite research agreement with Japan's National Institute of Infectious Diseases and Tottori University with respect to development of human antibodies against pathogenic viruses and toxins by utilizing fully human antibody-producing animals

Trans Chromosomics, Inc. ("TC", headquartered in Yonago City, Tottori Pref., Japan), the National Institute of Infectious Diseases ("NIID", headquartered in Shinjuku Ward, Tokyo, Japan) and Tottori University ("TU", whose Chromosome Engineering Research Center is located in Yonago City, Tottori Pref., Japan) have agreed to conduct a tripartite research concerning human antibodies against pathogenic viruses and toxins by utilizing the proprietary fully human antibody-producing animals and TC and TU.

The tripartite research for "establishing the basis to develop therapeutic antibodies and vaccines against pathogenic viruses and toxins" aims specifically at the following:

- (1) Development of monoclonal antibody seeds for treatment of hepatitis A infection
- (2) Development of monoclonal antibody seeds for treatment of hepatitis E infection
- (3) Development of monoclonal antibody seeds for neutralizing bacterial, snake and spider toxins

Under this research agreement, TC and TU are to provide NIID with their fully human antibody-producing animals, with which NIID is to implement the afore-mentioned development.

TC holds the right to commercialize fully human antibodies to be obtained through the joint research and aims to put them into practical applications through license-out to pharmaceutical companies.